The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...
Lentiviral vectors have emerged as indispensable tools in gene therapy, offering the ability to integrate therapeutic genes into both dividing and non-dividing cells. Their unique capacity to achieve ...
Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "Viral Vector Manufacturing Markets and Technologies Through 2030" report has been added to ResearchAndMarkets.com's offering. The global market for viral ...
CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery solutions, is excited to announce that it’s received the BioIndustrial Innovation of the Year award by the BioTech ...
Fully deleted adenovirus vectors (FD-AdVs) would appear to be promising tools for gene therapy. Since these vectors are deleted of all adenoviral genes, they require a helper adenovirus for their ...
Developers can now leverage the robustness and reliability of PostgreSQL for AI while minimizing operational complexity, increasing efficiency and achieving faster search speeds Timescale, the cloud ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback